Disregarding the patients classified as L3, those with the L2 variant showed an inferior disease free survival to that of the remainder (p < 0-01), and more of them failed to remit after receiving "standard" remission induction treatment (p < 0.01). They included an excess of older children (p < 0 01) with less profound marrow failure at diagnosis, and fewer of them expressed the common ALL antigen (p = 0 05). There was no association between L2 morphology and the diagnostic white cell count, sex, or the presence of a mediastinal mass.
Since effective treatment for childhood lymphoblastic leukaemia (ALL) was developed repeated attempts have been made to identify clinical and pathological features related to prognosis. These efforts have been directed at refining treatment protocols and helping with the classification of what is clearly a heterogeneous group of disorders.
Blast cell morphology has recently enjoyed a renaissance as a prognostic factor, chiefly due to the introduction of the French American and British (FAB) cooperative group's classification of acute lymphoblastic leukaemia (ALL).' 2 Using their criteria, several authors in the past few years have sug- gested that the minority L2 variant is associated with a worse outlook.3-8 None the less, several unanswered questions remain. Can L2 disease be reproducibly identified by independent morphologists? What is its prevalence in a large Accepted for publication 23 April 1986 unselected series? Is the association with poor treatment response due to a higher relapse rate or lower remission induction rate? Is L2 morphology of independent prognostic importance or is it associated with some other well known adverse feature such as older age, higher presenting leucocyte count, or male sex? In an attempt to answer some or all of these questions our study was conducted as part of a large multicentre trial.
Patient and methods
All children who were entered into the Medical Members of the Working Party:
Professor RM Hardisty (Chairman); Dr CC Bailey; Dr P Barbor; Dr ND Barnes; Dr C Barton; Dr SC Cartwright; Dr AW Craft; Dr JM Chessells; Dr SI Dempsey; Dr JH Durrant; Dr OB Eden; FAB morphological classification of childhood lymphoblastic leukaemia type recorded, either because no slides were received for review, or because the material submitted was technically inadequate. At the time of this report data on the fate of 91 were available: 33 (36%) had relapsed or died, which is a slightly higher proportion than that for the FAB typed group (219 of 738 or 30%). It may be that the group of 95 contained an excess of some subgroup, perhaps those with severe secondary myelofibrosis, which would have made marrow aspiration difficult. They seemed to be randomly distributed between the sexes and different age groups.
Discussion
The three morphological groups of ALL defined by the FAB group' 2 are grossly unevenly distributed. We found a prevalence of 86%, 13%, and 1% for Li, L2, and L3 types, respectively, in a group of 738 consecutive patients.
Dismissing the tiny group with L3 disease as morphologically, immunologically, cytogenetically, and clinically distinct-they are the B cell leukaemias-the main interest in typing the other ALLs by light microscopy was twofold. First, to find out whether they could be objectively and reproducibly subcategorised into two groups, and secondly, if so, whether such a classification had any clinical relevance.
Reliable typing does seem possible. Using the FAB group's scoring system,2 the measure of agreement reached between three independent haematologists in this study was as good as could reasonably be expected, the slides over which there was strong disagreement were usually of borderline technical adequacy. It was usually obvious whether a given case should be typed as Li or L2, even if the estimated proportion of cells showing a particular feature differed between observers. Some conclusions can be drawn from the UKALL VIII patients about the relevance of such a classification. L2 ALL occurs more commonly in older children, is associated with less profound bone marrow failure, and it also more often does not express the common ALL antigen. Apart from these distinguishing clinical features, there is also a trend emerging for patients with L2 disease to have a worse prognosis. Furthermore, the inferior disease free survival they display is not related to age, sex, or presenting white cell count. It may, in part, be due to the relatively high proportion of them who fail to achieve remission. For those who do remit there is a higher marrow relapse rate but no excess of extramedullary disease. Survival after relapse may be shorter for patients with L2 disease than for those with Li disease.
Some of these observations are new; others are not. The worse prognosis for patients with L2 disease was first noted in 1978 by a Hungarian group3 and later confirmed by Hann et al in the United Kingdom. 4 Viana et al5 not only indicated that patients with L2 disease had a poorer outlook but noted that more of them were older. This association with age was also commented on by the FAB group in 1981 when they refined their classification to include a scoring system for Ls and L2.2 Revision of their original criteria' meant that fewer children were classified as L2 (16% in their index series), but they did note that the prevalence of L2 disease was positively correlated with age.
The United States Children's Cancer Study Group (CCSG) modified the FAB scoring system further; and they assessed each case on a cell by cell basisthat is, calling each cell Li or L2 with each patient being classified according to the proportion of L2 cells present.6 7 This differs from the FAB scoring system, which is done on a feature by feature basis-that is, the proportion of cells showing a low nuclear: cytoplasmic ratio and so on-and where a final type is ascribed on the basis of a composite score from each of four features:2 Such a superficially subtle difference may be quite important and might explain why the CCSG recently found FAB type to be the second most important independent prognostic factor, which indicates speed of therapeutic response.7 It might also explain why fewer of their patients (< 10%) type as L2.
The CCSG also noted in their " 160 series" that the 37 patients with "pure" L2 disease (those with > 50% L2 cells) had a 16-3% remission failure rate compared with 3 5% for the 873 children with Li disease. The implicit suggestion contained in these figures is supported by our findings. Few patients with ALL fail to remit on current regimens, and there were only 15 such children in the whole of UKALL VIII, if failing to remit is defined as having detectable disease after 28 days of treatment. Seven of them typed as L2; a highly significant excess. Other new findings arising from our analysis are that L2 ALL is associated with less severe marrow failure at presentation and that it less commonly expresses the "common" ALL antigen; but these findings need to be confirmed.
The clinical importance of ALL FAB type seems to be fairly clear. L2 ALL is a more refractory disease and so is a logical candidate for alternative treatment. Such treatment should be different from the beginning, in view of the high remission failure rate. Whether L2 disease is a nosologically distinct disorder is less certain. If it is the CCSG may have defined it more precisely with their exclusive classification. Further information might be obtained from parallel cytogenetic studies, or from a similar morphological analysis of a large group of adults with ALL.
